openPR Logo
Press release

Onyx Scientific Ltd Receives French Research Tax Credit Accreditation

06-16-2010 09:09 AM CET | Health & Medicine

Press release from: Onyx Scientific Ltd

Onyx Scientific Ltd Receives French Research Tax Credit Accreditation
Onyx Scientific Ltd, the Contract Chemistry R&D Company is pleased to announce that it has received French research tax credit approval.
The French Ministry of Research (Ministère de l'Enseignement Supérieur et de la Recherche) has granted the French R&D tax credit ("Crédit d'Impôt Recherche", CIR) accreditation to Onyx Scientific as of June 2010. This initiative allows eligible French pharmaceutical, biotech and agricultural companies subject to corporate tax in France, the ability to claim significant tax relief on costs generated in R&D requirements that are outsourced to Onyx Scientific.
Dr Tony Flinn, Onyx Scientific Chief Executive Officer, comments: “This is great news for us as we needed to demonstrate our unique innovative culture on application. We are happy to employ this in the service of French biotech and pharmaceutical companies”
Additional information on the French research tax credit system is available from the Ministère de l'Enseignement Supérieur et de la Recherche site -

Onyx Scientific Limited is a chemistry Outsourcing specialist that supplies a diverse array of chemistry research and development services to the pharmaceutical and related industries. Onyx Scientific provides contract research, custom synthesis, small-scale cGMP manufacturing, polymorphism, salt selection and other services plus novel fine chemicals based on proprietary technology.

Onyx Scientific Ltd
Sunderland Enterprise Park East
Dr Tony Flinn

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Onyx Scientific Ltd Receives French Research Tax Credit Accreditation here

News-ID: 135195 • Views: 842

More Releases from Onyx Scientific Ltd

GMP Synthesis chemistry services organisation, Onyx Scientific, announce increas …
Leading chemistry services organisation, Onyx Scientific Ltd, is pleased to announce an increased demand for its early-phase, GMP synthesis, Investigational New Drug (IND) services for the development of Active Pharmaceutical Ingredients (APIs). “At Onyx we plan for success by focussing on detail” explains CEO Tony Flinn. “Our service driven systems deliver comprehensive chemical route development, efficient raw materials sourcing, thorough analysis and world-class solid-state characterization. We are recognised as the
Custom Synthesis chemistry services CRO, Onyx Scientific, hails the success of i …
Onyx Scientific, a trusted global chemistry services CRO and leading provider of high justified intermediates and APIs for both phase I and phase II clinical studies, hails the success of its world-class solid-state polymorph screening services for the increased demand for its international GMP-compliant Process Development capability. Onyx Scientific specialise in Medicinal Chemistry, Process Development, Custom Synthesis, GMP synthesis and Scale-up, in addition to a comprehensive range of Analytical and
Solid-state chemistry services CRO, Onyx Scientific reports increased demand for …
Experts in the provision of solid-state chemistry services for the pharmaceutical and biotech industries, leading global contract research organisation, Onyx Scientific, is delighted to report increased demand in taking candidate compounds from concept through to process development and scale-up of APIs for Phase I and Phase II clinical studies. “Handling difficult-to-crystallize materials is an art form as well as a science” explains Tony Flinn, CEO, Onyx Scientific. “Inherently complicated, the implications
GMP synthesis chemistry services CRO, Onyx Scientific, reports increased small s …
Internationally renowned, contract research organisation Onyx Scientific, is pleased to announce the continued growth of its small-scale GMP custom synthesis services for development APIs (Active Pharmaceutical Ingredients) Commenting on the growing success of its small-scale GMP synthesis services, CEO, Dr Tony Flinn says “our success is due to open communication and a highly responsive scientific team, who are able to lower the cost of a GMP process by

All 5 Releases